Sanofi Agrees to Buy Dynavax in $2.2 Billion All-Cash Deal
This week, French healthcare giant Sanofi announced it will buy Dynavax Technologies for $2.2 billion in cash. The all-cash deal values Dynavax above its recent stock price. This is major news in vaccines, especially for adult immunization. Sanofi will gain new products and early-stage vaccine candidates. The acquisition is expected to be completed in early 2026 after regulatory approvals.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
